ACB vs. CRON, THCX, DHT.UN, GUD, WEED, CPH, OGI, SUGR, FIRE, and EPI
Should you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include Cronos Group (CRON), Hydropothecary (THCX), DRI Healthcare Trust (DHT.UN), Knight Therapeutics (GUD), Canopy Growth (WEED), Cipher Pharmaceuticals (CPH), Organigram (OGI), SugarBud Craft Growers (SUGR), Supreme Cannabis (FIRE), and ESSA Pharma (EPI). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Aurora Cannabis vs. Its Competitors
Aurora Cannabis (TSE:ACB) and Cronos Group (TSE:CRON) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.
Aurora Cannabis has a beta of 1.087815, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.299122, indicating that its share price is 30% more volatile than the S&P 500.
In the previous week, Aurora Cannabis had 1 more articles in the media than Cronos Group. MarketBeat recorded 1 mentions for Aurora Cannabis and 0 mentions for Cronos Group. Aurora Cannabis' average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.
4.3% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 4.6% of Cronos Group shares are owned by institutional investors. 46.4% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Aurora Cannabis has a net margin of -22.55% compared to Cronos Group's net margin of -42.65%. Cronos Group's return on equity of -4.40% beat Aurora Cannabis' return on equity.
Aurora Cannabis presently has a consensus target price of C$8.75, suggesting a potential upside of 14.53%. Given Aurora Cannabis' stronger consensus rating and higher probable upside, research analysts plainly believe Aurora Cannabis is more favorable than Cronos Group.
Cronos Group has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.
Summary
Cronos Group beats Aurora Cannabis on 8 of the 15 factors compared between the two stocks.
Get Aurora Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurora Cannabis Competitors List
Related Companies and Tools
This page (TSE:ACB) was last updated on 10/10/2025 by MarketBeat.com Staff
